Ribo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme

Bulletin Express06-08

On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months.

The initiative comprises two parallel tranches:

1. H-Share Incentive Scheme Purchase • Up to RMB100.00 million of internal funds will be provided to an independent trustee to buy existing H-shares on-market for future awards under the company’s H-Share Incentive Scheme. • Any share grants funded by these purchases will follow Rule 17.12 of the Hong Kong Listing Rules.

2. General Mandate Share Repurchase • Separately, up to RMB100.00 million will be used under the general mandate approved at the 5 June 2026 AGM to repurchase H-shares in the open market. • Repurchased shares will be held as treasury stock.

Management highlighted that the dual programme signals confidence in the group’s business outlook while maintaining a solid financial position. The timing, volume and execution price of each transaction remain subject to market conditions and board discretion.

The company confirmed that all activities will adhere to its Articles of Association, the Hong Kong Listing Rules and other applicable regulations. Shareholders and potential investors were advised to exercise caution when trading the company’s securities, given that actual purchase and repurchase volumes are not assured.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152243913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152243913","market":"hk","top_or_hot":-1,"title":"Ribo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme","media":"Bulletin Express","content":"<p>On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months.</p>\n<p>The initiative comprises two parallel tranches:</p>\n<p>1. H-Share Incentive Scheme Purchase  \n   • Up to RMB100.00 million of internal funds will be provided to an independent trustee to buy existing H-shares on-market for future awards under the company’s H-Share Incentive Scheme.  \n   • Any share grants funded by these purchases will follow Rule 17.12 of the Hong Kong Listing Rules.</p>\n<p>2. General Mandate Share Repurchase  \n   • Separately, up to RMB100.00 million will be used under the general mandate approved at the 5 June 2026 AGM to repurchase H-shares in the open market.  \n   • Repurchased shares will be held as treasury stock.</p>\n<p>Management highlighted that the dual programme signals confidence in the group’s business outlook while maintaining a solid financial position. The timing, volume and execution price of each transaction remain subject to market conditions and board discretion.</p>\n<p>The company confirmed that all activities will adhere to its Articles of Association, the Hong Kong Listing Rules and other applicable regulations. Shareholders and potential investors were advised to exercise caution when trading the company’s securities, given that actual purchase and repurchase volumes are not assured.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months.</p>\n<p>The initiative comprises two parallel tranches:</p>\n<p>1. H-Share Incentive Scheme Purchase  \n   • Up to RMB100.00 million of internal funds will be provided to an independent trustee to buy existing H-shares on-market for future awards under the company’s H-Share Incentive Scheme.  \n   • Any share grants funded by these purchases will follow Rule 17.12 of the Hong Kong Listing Rules.</p>\n<p>2. General Mandate Share Repurchase  \n   • Separately, up to RMB100.00 million will be used under the general mandate approved at the 5 June 2026 AGM to repurchase H-shares in the open market.  \n   • Repurchased shares will be held as treasury stock.</p>\n<p>Management highlighted that the dual programme signals confidence in the group’s business outlook while maintaining a solid financial position. The timing, volume and execution price of each transaction remain subject to market conditions and board discretion.</p>\n<p>The company confirmed that all activities will adhere to its Articles of Association, the Hong Kong Listing Rules and other applicable regulations. Shareholders and potential investors were advised to exercise caution when trading the company’s securities, given that actual purchase and repurchase volumes are not assured.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1152243913","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152243913","pubTimestamp":1780908262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"日博生命科学宣布最多人民币2亿元H股购买及回购计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months.\nThe initiative comprises two parallel tranches:\n1. H-Share Incentive Scheme Purchase  \n   • Up to RMB100.00 million of internal funds will be provided to an independent trustee to buy existing H-shares on-market for future awards under the company’s H-Share Incentive Scheme.  \n   • Any share grants funded by these purchases will follow Rule 17.12 of the Hong Kong Listing Rules.\n2. General Mandate Share Repurchase  \n   • Separately, up to RMB100.00 million will be used under the general mandate approved at the 5 June 2026 AGM to repurchase H-shares in the open market.  \n   • Repurchased shares will be held as treasury stock.\nManagement highlighted that the dual programme signals confidence in the group’s business outlook while maintaining a solid financial position. The timing, volume and execution price of each transaction remain subject to market conditions and board discretion.\nThe company confirmed that all activities will adhere to its Articles of Association, the Hong Kong Listing Rules and other applicable regulations. Shareholders and potential investors were advised to exercise caution when trading the company’s securities, given that actual purchase and repurchase volumes are not assured.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152243913","isCrawlerRequest":true}